Liminatus Pharma, Inc.
LIMN
$3.84
$0.205.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.52M | -11.00M | -10.21M | -2.27M | -1.05M |
| Total Depreciation and Amortization | 2.00K | 2.20K | 1.70K | 1.20K | 700.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.52M | 7.23M | 7.23M | -166.30K | -1.27M |
| Change in Net Operating Assets | 31.50K | -8.05M | -6.98M | -7.28M | -7.01M |
| Cash from Operations | -3.97M | -11.82M | -9.96M | -9.72M | -9.32M |
| Capital Expenditure | -13.10K | -13.10K | -13.10K | -13.10K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -200.00K | -775.00K | -1.33M | -2.13M |
| Cash from Investing | -13.10K | -213.10K | -788.10K | -1.34M | -2.13M |
| Total Debt Issued | 0.00 | 3.63M | 4.34M | 5.04M | 6.02M |
| Total Debt Repaid | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Issuance of Common Stock | 3.80M | 14.14M | 10.56M | 10.56M | 10.56M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.86M | -3.86M | -3.86M | -3.86M | -3.83M |
| Cash from Financing | 5.66M | 13.91M | 11.03M | 11.73M | 12.75M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.68M | 1.87M | 281.40K | 677.50K | 1.30M |